Ibrutinib

Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues Were $1.121 Billion First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.282 Billion, an Increase of 16.1 Percent on a Reported Basis, or 17.0 Percent on an Operational Basis; Global Vraylar Net Revenues Were $765 Million; Global Botox Therapeutic Net Revenues Were $866 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $433 Million First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.633 Billion, an Increase of 5.8 Percent on a Reported Basis, or 7.5 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $738 Million; Global Venclexta Net Revenues Were $665 Million; Global Elahere Net Revenues Were $179 Million First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.102 Billion, a Decrease of 11.7 Percent on a Reported Basis, or 10.2 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $556 Million; Global Juvederm Net Revenues Were $231 Million Raises 2025 Adjusted Diluted EPS Guidance Range from $11.99 - $12.19 to $12.09 - $12.29, which Includes an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the First Quarter 2025 NORTH CHICAGO, Ill., April 25, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2025. "AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year," said Robert A. Michael, chief executive officer, AbbVie. "The fundamentals of our business are strong and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term." First -Quarter Results Worldwide net revenues were $13.343 billion, an increase of 8.4 percent on a reported basis, or 9.8 percent on an operational basis. Global net revenues from the immunology portfolio were $6.264 billion, an increase of 16.6 percent on a reported basis, or 18.1 percent on an operational basis. Global Skyrizi net revenues were $3.425 billion, an increase of 70.5 percent on a reported basis, or 72.0 percent on an operational basis. Global Rinvoq net revenues were $1.718 billion, an increase of 57.2 percent on a reported basis, or 59.7 percent on an operational basis. Global Humira net revenues were $1.121 billion, a decrease of 50.6 percent on a reported basis, or 49.5 percent on an operational basis. Global net revenues from the neuroscience portfolio were $2.282 billion, an increase of 16.1 percent on a reported basis, or 17.0 percent on an operational basis. Global Vraylar net revenues were $765 million, an increase of 10.3 percent. Global Botox Therapeutic net revenues were $866 million, an increase of 15.8 percent on a reported basis, or 17.0 percent on an operational basis. Global Ubrelvy net revenues were $240 million, an increase of 17.8 percent on a reported basis, or 18.0 percent on an operational basis. Global Qulipta net revenues were $193 million, an increase of 47.6 percent on a reported basis, or 48.3 percent on an operational basis. Global net revenues from the oncology portfolio were $1.633 billion, an increase of 5.8 percent on a reported basis, or 7.5 percent on an operational basis. Global Imbruvica net revenues were $738 million, a decrease of 11.9 percent. Global Venclexta net revenues were $665 million, an increase of 8.3 percent on a reported basis, or 12.3 percent on an operational basis. Global Elahere net revenues were $179 million. Global net revenues from the aesthetics portfolio were $1.102 billion, a decrease of 11.7 percent on a reported basis, or 10.2 percent on an operational basis. Global Botox Cosmetic net revenues were $556 million, a decrease of 12.3 percent on a reported basis, or 10.7 percent on an operational basis. Global Juvederm net revenues were $231 million, a decrease of 22.2 percent on a reported basis, or 20.0 percent on an operational basis. On a GAAP basis, gross margin in the first quarter was 70.0 percent. The adjusted gross margin was 84.1 percent. On a GAAP basis, selling, general and administrative (SG&A) expense was 24.7 percent of net revenues. The adjusted SG&A expense was 24.6 percent of net revenues. On a GAAP basis, research and development (R&D) expense was 15.5 percent of net revenues. The adjusted R&D expense was 15.4 percent of net revenues. Acquired IPR&D and milestones expense was 1.9 percent of net revenues. On a GAAP basis, operating margin in the first quarter was 28.0 percent. The adjusted operating margin was 42.3 percent. Net interest expense was $627 million. On a GAAP basis, the tax rate in the quarter was 22.4 percent. The adjusted tax rate was 14.2 percent. Diluted EPS in the first quarter was $0.72 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.46. These results include an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense. Recent Events AbbVie announced that its board of directors unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman of the board of directors, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. AbbVie announced that the European Commission (EC) granted marketing authorization to Rinvoq (upadacitinib) for the treatment of giant cell arteritis (GCA) in adult patients. The approval was supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that Rinvoq achieved the primary endpoint of sustained remission and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission. This authorization marks the eighth approved indication for Rinvoq in the European Union (EU). At the Society of Gynecologic Oncology (SGO) Annual Meeting, AbbVie announced final data analysis from the Phase 3 MIRASOL trial evaluating the efficacy and safety of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with Elahere continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator's choice (IC) chemotherapy. AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company, announced a collaboration and option-to-license agreement that will combine AbbVie's oncology expertise with Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers, for people living with cancer. AbbVie announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines. TrenibotulinumtoxinE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration and short duration of effect of 2-3 weeks. If approved, trenibotulinumtoxinE will be the first neurotoxin of its kind available to patients. Allergan Aesthetics announced that the Allergan Medical Institute (AMI) will open three new state-of-the-art training centers in the U.S., expanding access to high-quality, tailored training for licensed aesthetics providers. The first training center is scheduled to open in Irvine, CA, with additional locations to follow in Atlanta, GA and Austin, TX. AbbVie and Gubra announced a license agreement to develop GUB014295 (ABBV-295), a potential best-in-class, long-acting amylin analog for the treatment of obesity. This partnership marks AbbVie's entrance into the obesity field and under the terms of the agreement, AbbVie will lead development and commercialization of GUB014295 globally. Prior to the close of the agreement, Gubra announced positive interim results from Part A of a Phase 1 multiple ascending dose (MAD) study, which showed that GUB014295 was well tolerated with body weight loss that was sustained in a manner consistent with data from a previously announced single ascending dose (SAD) study. AbbVie announced that the FDA approved Emblaveo (aztreonam and avibactam), as the first monobactam/β-lactamase inhibitor combination antibiotic therapy to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria. The approval of Emblaveo was supported by prior findings regarding the efficacy and safety of aztreonam for the treatment of complicated intra-abdominal infections as well as clinical trial results from the Phase 3 REVISIT study, which evaluated the efficacy, safety, and tolerability of Emblaveo for the treatment of serious infections due to Gram-negative bacteria. Full-Year 2025 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.99 - $12.19 to $12.09 - $12.29, which includes an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2025. The company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2025, as both cannot be reliably forecasted. This guidance does not reflect the acquired IPR&D and milestones impact related to AbbVie and Gubra's licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025. Additionally, this guidance is based on the existing trade environment and does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie's business. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, neuroscience, oncology, and eye care - and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on X (formerly Twitter), Facebook, Instagram, YouTube or LinkedIn. Conference Call AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our first-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time. Non-GAAP Financial Results Financial results for 2025 and 2024 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. SOURCE AbbVie WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

点击蓝字关注我们编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。作为全球规模最大、学术水平最高、最具权威性的国际肿瘤会议之一，2025年ASCO年会将汇聚顶级肿瘤专家、学者和行业领袖，共探肿瘤领域的前沿研究成果和先进治疗方法。日前，2025 ASCO入选摘要标题（包括Late-Breaking Abstracts）已发布。摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布。《肿瘤瞭望-血液时讯》特别整理血液肿瘤领域的重磅研究，包括1项LBA、27项口头报告、27项快速口头报告，助力大家提前了解会议的重磅内容。01Plenary Session当地时间：6月1日13:00-16:00报告地点：Hall B1摘要号：LBA3英文标题：Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)中文标题：：rusfertide治疗真性红细胞增多症（PV）的三期、双盲、安慰剂（PBO）对照VERIFY研究结果讲者：Andrew Tucker Kuykendall, MD| Moffitt Cancer Center02Oral Abstract Session淋巴瘤与慢性淋巴细胞白血病当地时间：5月30日14:45–17:45报告地点：S100a摘要号：7000英文标题：Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial中文标题：通过PhasED-Seq对国家试验中DLBCL患者治疗结束ctDNA MRD的前瞻性验证讲者：Steven Wang, MD | Amsterdam UMC Location Vrije Universiteit摘要号：7001英文标题：Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group中文标题：自然杀伤性 T 细胞淋巴瘤分期系统修订：中国西南肿瘤学组及亚洲淋巴瘤研究组多中心研究讲者：林桐榆（四川省肿瘤医院）摘要号：7002英文标题：Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses中文标题：不同组织学分级滤泡性淋巴瘤的分子图谱：来自基因组和转录组分析的见解讲者：孙聪（天津医科大学肿瘤医院）摘要号：7003英文标题：A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)中文标题：KITE-363抗CD19/CD20嵌合抗原受体（CAR）T细胞治疗复发/难治性B细胞淋巴瘤患者的Ⅰ期临床研究讲者：Saurabh Dahiya, MD, FACP | Stanford University School of Medicine摘要号：7004英文标题：Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma中文标题：多病毒特异性T细胞用于增强双特异性抗体在淋巴瘤中的治疗活性讲者：Akiva Diamond, MD | Department of Medicine, Section of Hematology-Oncology, Baylor College of Medicine; Baylor St.Luke’s Medical Center; Dan L Duncan Comprehensive Cancer Center摘要号：7005英文标题：WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma中文标题：WaveLINE-003：zilovertamab vedotin联合标准治疗用于复发/难治性弥漫大B细胞淋巴瘤的Ⅱ/Ⅲ期临床试验讲者：Philippe Armand, MD, PhD | Dana-Farber Cancer Institute摘要号：7006英文标题：Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)中文标题：信迪利单抗（抗PD-1抗体）联合西达本胺（一种口服HDACi）继以 P-GemOx 方案治疗初治结外自然杀伤性 /T 细胞淋巴瘤（TN-ENKTL）患者的多中心、开放标签、单臂、II 期研究（SCENT-2 试验）讲者：黄慧强（中山大学肿瘤防治中心）摘要号：7007英文标题：Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21)中文标题：信迪利单抗（抗PD-1）联合依托泊苷（ICE）方案用于二线治疗经典霍奇金淋巴瘤（cHL）：一项多中心、随机、对照、双盲 III 期研究（ORIENT-21）的结果讲者：刘鹏（中国医学科学院肿瘤医院）摘要号：7008英文标题：Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)中文标题：先天细胞接合剂acimtamig（AFM13）联合AlloNK（AB-101）治疗复发或难治性经典型霍奇金淋巴瘤的Ⅱ期临床试验剂量探索部分结果（LuminICE-203）讲者：Joseph E. Maakaron, MD | Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：6月2日15:00-18:00报告地点：S100a摘要号：6500英文标题：Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial中文标题：Ropeginterferon alfa-2b vs. anagrelide治疗原发性血小板增多症：SURPASS-ET Ⅲ期临床试验的主要结果讲者：Ruben A. Mesa, MD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine摘要号：6501英文标题：Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)中文标题：asciminib（ASC）vs. nilotinib（NIL）用于新诊断慢性期慢性粒细胞白血病（CML-CP）患者的不良事件导致治疗中断时间（TTDAE）:ASC4START Ⅲb期临床试验主要终点结果讲者：Andreas Hochhaus, MD | Klinik für Innere Medizin II, Universitätsklinikum Jena摘要号：6502英文标题：Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study中文标题：CADENZA研究中pivekimab sunirine（PVEK）治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）患者的疗效与安全性讲者：Naveen Pemmaraju, MD | The University of Texas MD Anderson Cancer Center摘要号：6503英文标题：Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes中文标题：克拉屈滨、低剂量阿糖胞苷联合维奈克拉与阿扎胞苷联合维奈克拉交替治疗高危慢性粒单核细胞白血病和骨髓增生异常综合征的Ⅱ期临床研究讲者：Guillermo Montalban-Bravo, MD | The University of Texas MD Anderson Cancer Center摘要号：6504英文标题：An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts中文标题：全口服方案decitabine-cedazuridine（DEC-C）联合维奈克拉（VEN）用于不适合强化诱导化疗的新诊断急性髓系白血病（AML）患者：来自101例患者的Ⅱ期队列研究结果讲者：Amer Methqal Zeidan, MBBS | Yale University School of Medicine摘要号：6505英文标题：Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies中文标题：lisaftoclax（APG-2575）联合阿扎胞苷（AZA）治疗初治或既往接受过维奈克拉（VEN）治疗的髓系恶性肿瘤患者的Ⅰb/Ⅱ期临床研究讲者：Michael Francis Leahy, FRACP, FRCP, FRCPath, MBChB | Royal Perth Hospital摘要号：6506英文标题：Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study中文标题：Ziftomenib治疗复发/难治性（R/R）NPM1突变急性髓系白血病（AML）：关键KOMET-001研究中Ⅰb/Ⅱ期临床疗效和安全性结果讲者：Eunice S. Wang, MD | Roswell Park Comprehensive Cancer Center摘要号：6507英文标题：γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION中文标题：γ9δ2 T细胞激活（γδTCA）联合ICT01和阿扎胞苷-维奈克拉（AV）治疗高龄/unfit新诊断急性髓系白血病（AML）成年患者：EVICTION Ⅰ/Ⅱ期研究中的初步疗效和剂量选择讲者：Pierre Yves Dumas, MD, PhD| CHU摘要号：6508英文标题：Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation中文标题：接受异基因造血干细胞移植后存活超过2年患者的长期结局讲者：Arjun Datt Law, MD, DM, MBBS, FCRP | Princess Margaret Cancer Centre浆细胞病当地时间：6月3日09:45-12:45报告地点：S100bc摘要号：7500英文标题：MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial中文标题：在适合移植的新诊断多发性骨髓瘤（NDMM）患者中，IsaKRD诱导后MRD驱动策略：MIDAS Ⅲ期临床试验的主要终点讲者：Aurore Perrot, MD, PhD | Toulouse University, CHU Oncopole摘要号：7501英文标题：Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial中文标题：皮下注射达雷妥尤单抗（Dara）+硼替佐米/来那度胺/地塞米松（VRd）联合达雷妥尤单抗+来那度胺（DR）维持治疗适合移植（TE）新诊断多发性骨髓瘤（NDMM）患者：PERSEUS Ⅲ期临床试验中持续微小残留病（MRD）阴性的分析讲者：Philippe Moreau, MD, PhD | University Hospital Hôtel-Dieu摘要号：7502英文标题：Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)中文标题：卡非佐米-来那度胺-地塞米松联合或不联合艾沙妥昔单抗（Isatuximab）治疗新诊断多发性骨髓瘤患者：Ⅲ期IsKia临床试验中的持续微小残留病（MRD）阴性分析讲者：Francesca Gay, MD, PhD | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino摘要号：7503英文标题：Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial中文标题：卡非佐米、来那度胺和地塞米松（KRd）联合或不联合达雷妥尤单抗（D）治疗新诊断多发性骨髓瘤（NDMM）患者的随机多中心研究：ADVANCE临床试验讲者：Carl Ola Landgren, MD, PhD | Myeloma Program and Experimental Therapeutics Program, University of Miami摘要号：7504英文标题：Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1中文标题：Elranatamab联合达雷妥尤单抗和来那度胺（EDR）治疗不适合接受移植的新诊断多发性骨髓瘤（NDMM）患者：MagnetisMM-6 part 1的初步结果讲者：HANG QUACH, MD, FRACP, FRCPA | St Vincent’s Hospital Melbourne, University of Melbourne摘要号：7505英文标题：First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results中文标题：JNJ-79635322（JNJ-5322）新型三特异性抗体（TsAb）在复发/难治性多发性骨髓瘤（RRMM）患者中的首次人体研究：初步Ⅰ期结果讲者：Niels W.C.J. van de Donk, MD, PhD | Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology摘要号：7506英文标题：Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study中文标题：艾沙妥昔单抗（Isa）通过体外输送系统（OBDS）皮下（SC）给药vs. Isa静脉注射（IV），联合泊马度胺和地塞米松（Pd）治疗复发/难治性多发性骨髓瘤（RRMM）：随机非劣效性Ⅲ期IRAKLIA研究结果讲者：Xavier P. Leleu, MD, PhD | Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402摘要号：7507英文标题：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)中文标题：CARTITUDE-1研究中接受ciltacabtagene autoleucel（cilta-cel）治疗的复发/难治性多发性骨髓瘤（RRMM）患者的长期（≥5年）缓解与生存情况讲者：Peter M. Voorhees, MD | Atrium Health / Levine Cancer Institute, Wake Forest University School of Medicine摘要号：7508英文标题：Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201中文标题：Nexicart-2的安全性与疗效数据：CAR-T在R/R轻链淀粉样变中的首次美国试验（Nxc-201）讲者：Heather Jolie Landau, MD | Memorial Sloan Kettering Cancer Center03Rapid Oral Abstract Session白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：5月30日13:00-14:30报告地点：E450a摘要号：6509英文标题：A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults中文标题：asciminib联合达沙替尼、泼尼松和贝林妥欧单抗治疗成人Ph阳性急性白血病的Ⅰ期临床研究讲者：Marlise R Luskin, MD | Dana-Farber Cancer Institute摘要号：6510英文标题：MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis中文标题：PhALLCON Ⅲ期临床试验中诱导治疗结束后的MRD阴性率：事后分析讲者：Ibrahim Aldoss, MD | City of Hope – Duarte摘要号：6511英文标题：Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation中文标题：减量PTCy用于接受配型无关供者异基因造血干细胞移植的急性髓系白血病患者讲者：Nihar Desai, MD, DM | Princess Margaret Hospital摘要号：6512英文标题：Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial中文标题：COMMANDS研究中luspatercept（LUSPA）对比促红素α（epoetin alfa，EA）治疗未使用促红素治疗的极低、低或中危骨髓增生异常综合征（MDS）患者的总体生存期（OS）与获得输血独立（TI）后反应持续时间分析讲者：Guillermo Garcia-Manero, MD | University of Texas MD Anderson Cancer Center摘要号：6513英文标题：Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study中文标题：bexmarilimab联合阿扎胞苷抑制巨噬细胞检查点Clever-1治疗骨髓增生异常综合征的疗效：BEXMAB Ⅰ/Ⅱ期研究结果讲者：Naval Guastad Daver, MD | Department of Leukemia, The University of Texas MD Anderson Cancer Center摘要号：6514英文标题：Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML中文标题：地西他滨和维奈克拉用于诱导终末分化，以改善TP53突变型MDS和AML的治疗结局讲者：Mendel Goldfinger, MD | Montefiore Einstein Comprehensive Cancer Center摘要号：6515英文标题：IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF)中文标题：IMproveMF更新：imetelstat（IME）联合芦可替尼（RUX）治疗中危1（INT-1）、中危2（INT-2）或高危（HR）骨髓纤维化（MF）患者的Ⅰ/Ⅰb期临床试验讲者：John Mascarenhas, MD | Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai摘要号：6516英文标题：Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial中文标题：asciminib（ASC）治疗接受过1种酪氨酸激酶抑制剂（TKI）治疗的慢性期慢性髓性白血病（CML-CP）患者的疗效和安全性：Ⅱ期ASC2ESCALATE试验的中期分析（IA）讲者：David Jacob Andorsky, MD | Rocky Mountain Cancer Centers, US Oncology Research摘要号：6517英文标题：Age-related macular degeneration in individuals with clonal hematopoiesis中文标题：克隆性造血个体的年龄相关性黄斑变性讲者：Keishla Marie Arce-Ruiz, BS | McGraw/Patterson Center for Population Sciences, Dana-Farber Cancer Institute淋巴瘤与慢性淋巴细胞白血病当地时间：5月31日08:00-09:30报告地点：E450a摘要号：7009英文标题：Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D中文标题：zanubrutinib（zanu）联合维奈克拉（ven）治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）：SEQUOIA研究D组结果讲者：Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Center and University of Washington摘要号：7010英文标题：Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders中文标题：DZD8586 在经共价或非共价 BTK 抑制剂及 BTK 降解剂治疗后的 CLL/SLL 患者中的I/II期研究讲者：李建勇（江苏省人民医院）摘要号：7011英文标题：SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)中文标题：SEQUOIA研究5年随访，C组：前线zanubrutinib单药治疗del(17p)及未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者讲者：Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS | Alfred Hospital and Monash University摘要号：7012英文标题：A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma中文标题：一项1/2期研究：评估选择性 EZH2 抑制剂 XNW5004 在复发/难治性非霍奇金淋巴瘤患者中的安全性与有效性讲者：邱录贵[中国医学科学院血液病医院（中国医学科学院血液学研究所）]摘要号：7013英文标题：CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study中文标题：以 CD79b 为靶点的抗体偶联药物（ADC）SHR - A1912 联合R - GemOx方案用于复发 / 难治性（R/R）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的1b/2期研究数据讲者：李亚军（湖南省肿瘤医院）摘要号：7014英文标题：Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study中文标题：固定疗程皮下（SC）莫妥珠单抗（Mosun）治疗既往未治疗的高肿瘤负担滤泡性淋巴瘤（FL）患者：Ⅱ期MorningSun研究的中期结果讲者：Ian W. Flinn, MD, PhD | Tennessee Oncology and OneOncology摘要号：7015英文标题：Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO中文标题：格菲妥单抗联合吉西他滨和奥沙利铂（Glofit-GemOx）治疗复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者：STARGLO研究2年随访结果讲者：Jeremy S. Abramson, MD | Massachusetts General Hospital Cancer Center摘要号：7016英文标题：Worldwide experience of chronic active EBV infection: Retrospective cohort study中文标题：全球慢性活动性EBV感染经验：回顾性队列研究讲者：王欣然（华中科技大学同济医学院附属同济医院）摘要号：7017英文标题：Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study中文标题：伊布替尼联合维奈克拉一线治疗年龄较大或存在TP53突变的套细胞淋巴瘤（MCL）患者的疗效和安全性：SYMPATICO研究讲者：Michael Wang, MD | Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center创新性治疗—免疫疗法当地时间：6月1日11:15-12:45报告地点：S406摘要号：2514英文标题：Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL)中文标题：靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果讲者：李志铭（中山大学肿瘤防治中心）浆细胞病当地时间：6月2日08:00-09:30报告地点：E450b摘要号：7509英文标题：Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial中文标题：艾沙妥昔单抗、卡非佐米、来那度胺和地塞米松（Isa-KRd）治疗高危（HR）新诊断多发性骨髓瘤（NDMM）：GMMG-CONCEPT研究中适合移植（TE）患者全队列的首次报告讲者：Lisa B. Leypoldt, MD | University Medical Center Hamburg-Eppendorf摘要号：7510英文标题：Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合硼替佐米（BTZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的首次结果讲者：Xavier P. Leleu, MD, PhD | Hematology, CIC 1082, U1313, CHU, University摘要号：7511英文标题：Heterogeneity in the expression of GPRC5D between patients with multiple myeloma中文标题：多发性骨髓瘤患者中GPRC5D表达的异质性讲者：Harsh Parmar | John Theurer Cancer Center, Hackensack University Medical Center摘要号：7512英文标题：Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial中文标题：Belantamab mafodotin联合来那度胺/地塞米松治疗新诊断的中度fit和虚弱多发性骨髓瘤患者：来自Ⅰ/Ⅱ期BELARD临床试验的长期疗效和安全性结果讲者：Evangelos Terpos, MD, PhD | Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine摘要号：7513英文标题：Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合卡非佐米（CFZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的初步结果讲者：Salomon Manier, MD, PhD | Hematology Department, Lille University Hospital摘要号：7514英文标题：Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results中文标题：ISB 2001的Ⅰ期首次人体研究：一种针对BCMAxCD38xCD3的三特异性抗体治疗复发/难治性多发性骨髓瘤（RRMM）患者——剂量递增（DE）结果讲者：Eben I. Lichtman, MD | UNC Lineberger Comprehensive Cancer Center摘要号：7515英文标题：Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial中文标题：belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺、硼替佐米和地塞米松（PVd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的微小残留病（MRD）阴性率比较：来自DREAMM-8研究的分析讲者：Suzanne Trudel, MD | Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre摘要号：7516英文标题：Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study中文标题：达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松（DVRd）治疗新诊断多发性骨髓瘤（NDMM）患者：Ⅲ期CEPHEUS研究中不适合移植（TIE）患者的亚组分析讲者：Saad Z Usmani, MD, MBA, FRCP, FASCO | Memorial Sloan Kettering Cancer Center（来源：《肿瘤瞭望》编辑部）声 明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。